- Global Pharma News & Resources

Factor XA Inhibitors Drug Class to Lead the Global Anticoagulants Market Through 2026

The market report envelopes an all-in information of the global Anticoagulants market and the nature of the market growth over the foreseeable period. The report provides a comprehensive elaboration of the positives and negatives of the global Anticoagulants market with DROT and Porter’s Five Forces analysis. With SWOT analysis, the report offers detailed insights about different players operating within the Anticoagulants market. In addition, the analysts of the report have served the qualitative and quantitative scrutinizing of different micro- and macro-economic factors influencing the global Anticoagulants market.

The popularity of online pharmacies is growing at an unprecedented rate in the anticoagulants market, and these channels are projected to emerge as the standard distribution channel in the future. A rapid rise in sales from these channels is also attributable to the increasing demand for effective anticoagulant drugs in developing countries, which is influencing players in the anticoagulants market to target untapped countries with minimal investments in distribution establishments. However, frequent instances of patent expiry are offering a leeway to generic drugs, which is projected to impede the advancement of the anticoagulants market during the forecast period (2020-2026).

For detailed insights on enhancing your product footprint, request for a sample here –

The aforementioned insights are explored comprehensively, along with accurate data, in an exclusive study published by Fact.MR. According to the report, the sales of anticoagulants market is projected to trace a healthy growth trajectory, and grow ~1.6X during 2020-2026.\

Key Trends of Anticoagulants Market

  • The cost-effective attribute of conventional drugs, such as warfarin, is boosting consumers’ loyalty towards these drugs, thereby limiting the opportunities for anticoagulants.
  • Producers are leveraging the prowess of quality development by zooming in their focus on the development of products with fewer to nil side effects, as anticoagulants are found to have caused nausea, vomiting, and excessive bleeding in some patients.
  • The introduction of patient-assistance programs by leading players to cushion the high finances required for the production of anticoagulant drugs is expected to serve as an instrument to strategize customer acquisition and retention. Daiichi Sankyo—a leading player in the anticoagulants market—illustrates this strategy. The company offers the SAVAYSA Savings Card to eligible patients at US$ 4 for a 30-day prescription, and US$ 12 for a 90-day prescription.
  • The oral route of drug administration remains the standard method, with an estimated share of ~54% in 2020, in the anticoagulants market. Concerns regarding the sterilization of needles leading to contagious diseases and infections are offering an edge to the oral consumption of drugs.
  • Factor XA Inhibitors accounted for ~50% share in the anticoagulants market in 2019, and are likely to retain their dominance in the drug class during 2020-2026. These drugs do not have any food interactions, owing to minimal metabolism through the CYP450 system.

For critical insights on this market, request for methodology here –

Anticoagulants Market – Assessment of Key Segments

Authors of the report have segmented the anticoagulants market into key categories in order to study the market at a microscopic level. The key segments considered while bifurcating the anticoagulants market include:

Drug Class
  • Factor XA Inhibitors (NOAC/DOAC)
  • Heparins
  • Direct Thrombin Inhibitors
  • Vitamin K Antagonists
  • Deep Vein Thrombosis
  • Pulmonary Embolism
  • Atrial Fibrillation & Heart Attack
  • Others
Route of Administration
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

For in-depth competitive analysis, buy now –

Market Majors Develop Blockbuster Drugs; Local Players Rely on Generic Drugs

Despite the growing popularity of blockbuster drugs, the threat of patent expiration is a cause of high concern among players in the anticoagulants market, which necessitates efforts and capital in research & development activities. The introduction of effective drugs remains the key strategy of leading players particularly, as the production of generic drugs by local and regional players hard-hits the revenue of these players. A leading player, Boehringer Ingelheim GmbH, announced the launch of a research & development program to explore its capabilities, increase number of pipeline drugs, and, in turn, collaborate with external partners. However, as novel drugs are cost-prohibitive in nature, small- and mid-level players are expanding in the anticoagulants market through the introduction of generic drugs.

Read More Trending and Similar Reports from Fact.MR –

About Us:

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner.


US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
Visit Our Website:

Editor Details

Last Updated: 31-Aug-2021